Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (204)	1/29/1998 10:48:00 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 3559

MZ: You're correct, "profit can kill science (AMGN)". It need not be that way. We, as investors, need to continuously scan for companies that look outward for vision. If a non-biologist is hired as CEO, we should consider it a potential red flag until we see that arrogance won't block a relative capacity for innovation. Let me make it clear that I think Schleifer, ex-AMGN noose, is doing a very good job. I approached Binder, after news of the TKTX litigation, with a plan to mobilize a small portion of that AMGN cash to merge certain programs at CEGE and ARIA when they were low-profile and dirt cheap. AMGN politely considered the outline and rejected it. Hoechst, TKTX's partner, subsequently licensed epo expression technology from CEGE and signed the genomics deal with ARIA. We need to avoid the "invented here" syndrome. Hopefully, REGN didn't catch the disease. Binder did an incredible job of managing regulatory and marketing. He has failed miserably at managing R&D. We needed two years of Binder transitioning to a hybrid of Binder/Rathman. Too bad.... AMGN could have carried, with relative ease, the sector flagship role forward to make a serious impact on where dollars flow in the pharma sector. We all know that 3-ring binders contain and organize your best efforts, protecting them from outside elements. Cheers! Rick